Lifonebart (VHB937) vs SAR448851

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Alzheimer's Disease

Shared mechanism: TREM2 · full Alzheimer's Disease pipeline

Lifonebart (VHB937)

Developed by Novartis

Phase 2 in Alzheimer's Diseasemonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: September 2028 · NCT07094516 (registry estimate)

No aligned efficacy figure on record for this race.

SAR448851

Developed by Sanofi and partners

Phase 2 in Alzheimer's Diseasesmall molecule
Weak signal

NCT06343636 · Phase 1 · completed

The healthy-volunteer part of this trial randomly assigned participants to VG-3927 or a matching placebo under double-blind conditions, which is a real controlled design, but the Alzheimer's disease group received a single open-label dose with no comparator. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Adverse Events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: July 2029 · NCT07688213 (registry estimate)

Reported efficacy

Adverse Events (28 days post last dose): The phase 1 trial enrolled 115 participants across multiple cohorts to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of VG-3927. VG-3927 achieved a robust and dose-dependent reduction of soluble TREM2 of up to approximately 50% in cerebrospinal fluid, with the maximum reduction of approximately 50% at the 25 mg dose. All related adverse events were mild or moderate in severity and self-resolving without drug discontinuations, and no serious adverse events were reported.

Result source: NCT06343636

Results for Alzheimer's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLifonebart (VHB937)SAR448851
CDR-SB, change—Not reported—Not reported
ADAS-Cog11, change—Not reported—Not reported
ADCS-ADL, change—Not reported—Not reported
MMSE, change—Not reported—Not reported
Amyloid PET, change (centiloids)—Not reported—Not reported

CDR-SB, change

Lifonebart (VHB937)
—Not reported
SAR448851
—Not reported

ADAS-Cog11, change

Lifonebart (VHB937)
—Not reported
SAR448851
—Not reported

ADCS-ADL, change

Lifonebart (VHB937)
—Not reported
SAR448851
—Not reported

MMSE, change

Lifonebart (VHB937)
—Not reported
SAR448851
—Not reported

Amyloid PET, change (centiloids)

Lifonebart (VHB937)
—Not reported
SAR448851
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Lifonebart (VHB937): no structured comparison results are available for Alzheimer's Disease.

SAR448851: no structured comparison results are available for Alzheimer's Disease.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lifonebart (VHB937)'s landscape · SAR448851's landscape